Bio-Rad: Anti-Idiotypic Antibodies for Anti-Drug Antibody Assays
Website: https://www.bio-rad-antibodies.com/biotherapeutic-antibodies-drug-discovery.html
Contact: [email protected]
Profile: Bio-Rad
Bio-Rad’s portfolio of recombinant monoclonal antibodies against marketed biologic drugs covers the following specificities:
Abatacept, Adalimumab, Alemtuzumab, Bevacizumab, Cemiplimab, Certolizumab pegol, Cetuximab, Daratumumab, Denosumab, Eculizumab, Etanercept, Golimumab, Infliximab, Ipilimumab, Natalizumab, Nivolumab, Omalizumab, Palivizumab, Panitumumab, Pembrolizumab, Pertuzumab, Ranibizumab, Rituximab, Secukinumab, Tocilizumab, Trastuzumab, Ustekinumab, Vedolizumab
Bio-Rad has developed these highly specific, high affinity anti-biotherapeutic antibodies to support your preclinical research, clinical trials and patient monitoring for original and biosimilar products.
We offer fully human, monoclonal, inhibitory anti-idiotypic antibodies for all the above biologics, ideal as a surrogate positive control or reference standard in anti-drug antibody (ADA) immunogenicity assays. Every antibody sequence is known, and recombinant production methods and stringent quality control mean you are assured of a consistent supply throughout the time course of your study. Our aim is to help you succeed with your bioanalytical assays:
- Buy surrogate positive control for your biologic or biosimilar
- Design and optimize a selective and sensitive assay
- Get translatable and reproducible results